Agios is a biopharmaceutical company founded in 2008 and headquartered in Cambridge, Massachusetts, focused on developing therapies for rare diseases through the science of cellular metabolism. The company has progressed from its discovery stage to become a commercial-stage organisation, with its first rare disease therapy approved by the FDA for treating hemolytic anemia in adults with pyruvate kinase deficiency.
The company's pipeline includes mitapivat, an investigational medicine being evaluated for thalassemia and sickle cell disease, reflecting Agios's concentration on hematologic conditions and metabolic disorders. Its technical capabilities span drug discovery and development, clinical evaluation, research laboratory science, and commercial operations, complemented by patient and community engagement work.
Agios emphasises collaboration across its research, development, and commercial functions, with stated commitments to inclusion, diverse perspectives, and putting patients at the centre of its work. The company maintains relationships with patient communities, healthcare professionals, and scientific partners as part of its operational approach.
